AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3376911 — intervention group
Group type: COMPARATOR
Intervention: High Sat + Chol diet (high in saturated fatty acids and very high in cholesterol)
Number of subjects: 10
Study 31192831 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga breathing (pranayama)
Number of subjects: 0
Study 29151700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 46
Study 29151700 — intervention group
Group type: COMPARATOR
Intervention: LAM+ADV
Number of subjects: 46
Study 25784709 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 30
Study 25784709 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 30
Study 24649780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (MgSO4) 50 mg kg(‐1) in 10 mL within 10 min, followed by an infusion of MgSO4 10 mg kg(‐1) hr(‐1) IV in 4mL for 12 hrs
Number of subjects: 60
Study 24649780 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) in same volume and rate for 12 hrs
Number of subjects: 60
Study 24649780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (MgSO4)
Number of subjects: 60
Study 24649780 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 60
Study 22016437 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured risk assessment scales on experimental wards
Number of subjects: 597
Study 22016437 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgement on control wards
Number of subjects: 597
Study 18430311 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen
Number of subjects: 12
Study 18430311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 16436687 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory identification and recognition tasks in patients with MHE
Number of subjects: 12
Study 16436687 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 12
Study 16436687 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between olfactory tests and PSE-syndrome test score
Number of subjects: 12
Study 14701947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg) and tinidazole (600 mg) combination twice daily for 7 days (Group 1)
Number of subjects: 165
Study 14701947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg), azithromycin (1 gm) and secnidazole (2 mg) as one time dose (Group 2)
Number of subjects: 165
Study 14701947 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily) and metronidazole (200 mg thrice daily for 7 days (Group 3)
Number of subjects: 165
Study 11124072 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 11124072 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-control and cohort studies
Number of subjects: 0
Study 11124072 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine indices of benefit and harm
Number of subjects: 0
Study 11124072 — intervention group
Group type: COMPARATOR
Intervention: Traditional statistical methods
Number of subjects: 0
Study 9070501 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dolasetron mesylate
Number of subjects: 319
Study 9070501 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron mesylate
Number of subjects: 319
Study 9070501 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dolasetron mesylate
Number of subjects: 319
Study 9070501 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron mesylate
Number of subjects: 319
Study 9070501 — intervention group
Group type: COMPARATOR
Intervention: Control (no dolasetron)
Number of subjects: 319
Study 9070501 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of dolasetron
Number of subjects: 319
Study 8348504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin (50 mg per instillation)
Number of subjects: 161
Study 8348504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) (150 mg per instillation)
Number of subjects: 161
Study 8348504 — intervention group
Group type: COMPARATOR
Intervention: Control (resection only)
Number of subjects: 161
Study 2948430 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.02 mL/kg of a 0.5% solution)
Number of subjects: 48
Study 2948430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (2 mL of a 0.025% solution)
Number of subjects: 48
Study 2948430 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol plus ipratropium combination
Number of subjects: 48
Study 2948430 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose or full-dose combinations of salbutamol and ipratropium
Number of subjects: 48
Study 2948430 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 48
Study 30025399 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 150
Study 30025399 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 150
Study 25914397 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stent
Number of subjects: 577
Study 25914397 — intervention group
Group type: COMPARATOR
Intervention: Double stent
Number of subjects: 577
Study 25914397 — intervention group
Group type: COMPARATOR
Intervention: Bail-out double stenting
Number of subjects: 577
Study 25914397 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with zotarolimus-eluting stents
Number of subjects: 577
Study 25917626 — intervention group
Group type: EXPERIMENTAL
Intervention: Phleum pratense subcutaneous immunotherapy (6 weekly doses)
Number of subjects: 42
Study 25917626 — intervention group
Group type: EXPERIMENTAL
Intervention: Phleum pratense subcutaneous immunotherapy (8 weekly doses)
Number of subjects: 42
Study 25917626 — intervention group
Group type: EXPERIMENTAL
Intervention: Phleum pratense subcutaneous immunotherapy (eight doses, two clustered increasing doses over 3 weeks)
Number of subjects: 42
Study 25917626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42
Study 22642712 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage theories
Number of subjects: 0
Study 22642712 — intervention group
Group type: EXPERIMENTAL
Intervention: Order threats
Number of subjects: 0
Study 22642712 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage theory on Alzheimer's disease
Number of subjects: 0
Study 22642712 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat on theory preference
Number of subjects: 0
Study 22642712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed order of stages
Number of subjects: 0
Study 20975274 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate at a mean dose of 200 mg/day
Number of subjects: 182
Study 20975274 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone at a mean dose of 50 mg/day
Number of subjects: 182
Study 19055986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) in ARTS-II trial
Number of subjects: 607
Study 17003665 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 16
Study 17003665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12710563 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire exploring issues of information, informed consent, bio‐material, confidentiality and autonomy, and of prevention/intervention
Number of subjects: 17055
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Best visual acuity 0.5 (20/40) or worse in at least one eye
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Best visual acuity 0.5 or worse in both eyes
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive error as a cause of reduced uncorrected vision
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopia as a cause of reduced uncorrected vision
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Other causes of reduced uncorrected vision
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexplained causes of reduced uncorrected vision
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia (‐0.5 diopter or less) or hyperopia (2 diopters or greater)
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopia risk
Number of subjects: 5067
Study 10764850 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia risk
Number of subjects: 5067
Study 8610733 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy
Number of subjects: 35
Study 1414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 0
Study 1414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sucrose sulphate solution
Number of subjects: 0
Study 6379293 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with multiple trauma
Number of subjects: 26
Study 6379293 — intervention group
Group type: COMPARATOR
Intervention: Controls (normals)
Number of subjects: 26
Study 31499238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand gel sanitizer
Number of subjects: 0
Study 31499238 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30423587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (BA group, n=112)
Number of subjects: 336
Study 30423587 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTI group, n=112)
Number of subjects: 336
Study 30423587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physical therapies alone, n=112)
Number of subjects: 336
Study 26420517 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pill with sedative information
Number of subjects: 0
Study 26420517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham magnetic field
Number of subjects: 0
Study 26420517 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 24768204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive discussion group (5-hour group discussion about suicide risk assessment skills)
Number of subjects: 111
Study 24768204 — intervention group
Group type: COMPARATOR
Intervention: Control group (2-hour baseline suicide gatekeeper lecture)
Number of subjects: 111
Study 21987409 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil (collagen patch coated with human coagulation factors)
Number of subjects: 58
Study 21987409 — intervention group
Group type: COMPARATOR
Intervention: Standard technique only
Number of subjects: 58
Study 20163243 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2
Number of subjects: 16
Study 20163243 — intervention group
Group type: COMPARATOR
Intervention: iliac crest bone graft
Number of subjects: 16
Study 18025885 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation in patients with pre-ART CD4 cell count < 200 cells/mul
Number of subjects: 792
Study 18025885 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation in patients with pre-ART CD4 cell count 200-350 cells/mul
Number of subjects: 792
Study 18025885 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation in patients with pre-ART CD4 cell count > 350 cells/mul
Number of subjects: 792
Study 16054395 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric contractions
Number of subjects: 19
Study 16054395 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal firing rates in the TA muscle
Number of subjects: 19
Study 16054395 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in motor unit firing rate with fatigue
Number of subjects: 19
Study 12124856 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose extract of Tripterygium wilfordii Hook F (180 mg/day)
Number of subjects: 35
Study 12124856 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose extract of Tripterygium wilfordii Hook F (360 mg/day)
Number of subjects: 35
Study 12124856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12124856 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label extension (Low-dose)
Number of subjects: 35
Study 12124856 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label extension (High-dose)
Number of subjects: 35
Study 12124856 — intervention group
Group type: COMPARATOR
Intervention: Open-label extension (Placebo)
Number of subjects: 35
Study 10466239 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy with conventional regimens
Number of subjects: 0
Study 10466239 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 0
Study 7573018 — intervention group
Group type: COMPARATOR
Intervention: Traditional Dialysate (TD; ionized calcium concentration 1.75 mmol/L)
Number of subjects: 86
Study 7573018 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Calcium Dialysate (LCD; ionized calcium concentration 1.25 mmol/L)
Number of subjects: 86
Study 1979010 — intervention group
Group type: COMPARATOR
Intervention: Droperidol-fentanyl anaesthesia (control group)
Number of subjects: 20
Study 1979010 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol-fentanyl anaesthesia modified by addition of 0.5% isoflurane (isoflurane group)
Number of subjects: 20
Study 6783346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 20 mg as a micronized powder with lactose
Number of subjects: 10
Study 6783346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 20 mg as micropellets without lactose
Number of subjects: 10
Study 6783346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 20 mg as an aerosol
Number of subjects: 10
Study 6783346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30091001 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-relevant information co-presented with target items during location judgment task
Number of subjects: 0
Study 30091001 — intervention group
Group type: COMPARATOR
Intervention: Other-relevant information co-presented with target items during location judgment task
Number of subjects: 0
Study 30091001 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-relevant information co-presented with target items during color judgment task
Number of subjects: 0
Study 30091001 — intervention group
Group type: COMPARATOR
Intervention: Other-relevant information co-presented with target items during color judgment task
Number of subjects: 0
Study 28978349 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT)
Number of subjects: 90
Study 28978349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 90
Study 28978349 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 90
Study 26347103 — intervention group
Group type: EXPERIMENTAL
Intervention: Home parenteral nutrition (HPN)
Number of subjects: 579
Study 26347103 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on Cox proportional hazard regression modeling
Number of subjects: 579
Study 23628668 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group with sensor glove
Number of subjects: 14
Study 23628668 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 14
Study 21242686 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-coated polysulfone (Vit E PS) membrane
Number of subjects: 62
Study 21242686 — intervention group
Group type: COMPARATOR
Intervention: Non-vitamin E-coated polysulfone (PS) membrane
Number of subjects: 62
Study 19587626 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided tibial nerve block
Number of subjects: 18
Study 19587626 — intervention group
Group type: COMPARATOR
Intervention: Traditional landmark-based tibial nerve block
Number of subjects: 18
Study 17877506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 0
Study 17877506 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 17877506 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional corticosteroids
Number of subjects: 0
Study 17877506 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy options
Number of subjects: 0
Study 16260856 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy at the involved field, with 30 Gy delivered in 20 sessions
Number of subjects: 166
Study 16260856 — intervention group
Group type: COMPARATOR
Intervention: No radiation (control group)
Number of subjects: 166
Study 12200755 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 36
Study 10404803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg 4 times daily for 8 weeks
Number of subjects: 23
Study 10404803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10404803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 23
Study 7486110 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES; MW 200,000; substitution ratio 0.40‐0.55)
Number of subjects: 42
Study 7486110 — intervention group
Group type: COMPARATOR
Intervention: 3% modified fluid gelatin (GEL)
Number of subjects: 42
Study 7486110 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 42
Study 2079844 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Mode (SM) training program (walk/jog)
Number of subjects: 20
Study 2079844 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimode (MM) training program (walk/jog, cycle, arm crank)
Number of subjects: 20
Study 2079844 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 479384 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dezocine
Number of subjects: 10
Study 479384 — intervention group
Group type: COMPARATOR
Intervention: 10 mg morphine
Number of subjects: 10
Study 479384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30820560 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard FET technique
Number of subjects: 26
Study 30820560 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated FET technique
Number of subjects: 26
Study 28376815 — intervention group
Group type: EXPERIMENTAL
Intervention: EAMD
Number of subjects: 230
Study 28376815 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-average
Number of subjects: 230
Study 28376815 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-gaps
Number of subjects: 230
Study 28376815 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC
Number of subjects: 230
Study 28376815 — intervention group
Group type: EXPERIMENTAL
Intervention: SR
Number of subjects: 230
Study 28376815 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM
Number of subjects: 230
Study 26887207 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation (2 Hz, 3-5 mA) applied to bilateral LR 3, GB 34, TE 5, and LU 5 once every 12 hours for two days post-surgery
Number of subjects: 60
Study 26887207 — intervention group
Group type: COMPARATOR
Intervention: Control group with filiform needles adhered to acupoints without electrical stimulation
Number of subjects: 60
Study 26887207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received lower dose anesthetics (Fentanyl 250 μg + Flurbiprofen axetil 25 mg + normal saline 2 mL/h, Sauteralgyl if necessary)
Number of subjects: 60
Study 26887207 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group
Number of subjects: 60
Study 21949005 — intervention group
Group type: EXPERIMENTAL
Intervention: Target treatment group (2 hours of therapy and coaching each week)
Number of subjects: 51
Study 21949005 — intervention group
Group type: COMPARATOR
Intervention: Community treatment group (variety of services averaging 3.9 hours per week)
Number of subjects: 51
Study 21949005 — intervention group
Group type: EXPERIMENTAL
Intervention: Target treatment group
Number of subjects: 51
Study 21300680 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents born preterm
Number of subjects: 337
Study 21300680 — intervention group
Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 337
Study 19702088 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) after surgical operation and chemotherapy (group C)
Number of subjects: 77
Study 19702088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (group B)
Number of subjects: 77
Study 19702088 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery only (group A)
Number of subjects: 77
Study 19702088 — intervention group
Group type: COMPARATOR
Intervention: Control group (benign tumor, group D)
Number of subjects: 77
Study 16763508 — intervention group
Group type: EXPERIMENTAL
Intervention: High cutoff hemofiltration
Number of subjects: 30
Study 16763508 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemofiltration
Number of subjects: 30
Study 14561016 — intervention group
Group type: COMPARATOR
Intervention: Cardioselective beta-blockers (single dose)
Number of subjects: 19
Study 14561016 — intervention group
Group type: COMPARATOR
Intervention: Cardioselective beta-blockers (longer duration)
Number of subjects: 19
Study 14561016 — intervention group
Group type: COMPARATOR
Intervention: Cardioselective beta-blockers
Number of subjects: 19
Study 10898408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg) plus ISMN (20 mg twice a day)
Number of subjects: 31
Study 10898408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg) plus GTN (500 microg)
Number of subjects: 31
Study 10898408 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ISMN (20 mg twice a day)
Number of subjects: 31
Study 10898408 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus GTN (500 microg)
Number of subjects: 31
Study 8599314 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (153 micromol or 10 mg Zn/d)
Number of subjects: 146